Literature DB >> 7075110

Cefsulodin kinetics in renal impairment.

T P Gibson, G R Granneman, J E Kallal, L T Sennello.   

Abstract

Cefsulodin kinetics were determined after a 500-mg dose to normal subjects and patients with varying degrees of renal insufficiency, including those requiring hemodialysis. Elimination kinetics were described by a two-compartment model. Steady-state volume of distribution was 0.26 l/kg regardless of renal function. When glomerular filtration rate (GFR) was more than 80 ml/min, elimination half-life (t1/2) was 1.9 hr, total body clearance (ClT) was 2.01 ml/kg/min, and renal clearance (ClR) was 1.09 ml/kg/ in. When GFR ranged from 79 to 53 ml/min, t1/2 was 2.9 hr, ClT was 1.17 ml/kg/min, and ClR was 0.65 ml/kg/min. In subjects with moderate renal failure in whom GFR was 32 to 22 ml/min, t1/2 was 5.7 hr, Clt was 0.66 ml/kg/min, and ClR was 0.26 ml/kg/min. In anuric patients t1/2 was 13.0 hr. and ClT was 0.19 ml/kg/min or 9.5% of ClT in normal subjects. There was a linear relationship between ClT and GFR such that ClT = 0.19 + 0.017 GFR (r = 0.95). During hemodialysis the average plasma flow was 122 ml/min, dialyzer plasma clearance was 50.9 ml/min, plasma drug concentration was reduced by 60%, and t1/2 fell to 2.1 hr. After dialysis the elimination rate appeared to return to that in nondialysis studies. Therefore, renal failure reduces the ClT of cefsulodin. In hemodialysis patients the maintenance dose of cefsulodin should be reduced to 10% of normal and 60% of the dose should be given after hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7075110     DOI: 10.1038/clpt.1982.84

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  Increased renal clearance of cefsulodin due to higher glomerular filtration rate in cystic fibrosis.

Authors:  A Hedman; G Alván; B Strandvik; A Arvidsson
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Deconvolution applied to the kinetics of extracorporal drug removal. Haemodialysis of cefsulodin.

Authors:  W R Gillespie; P Veng-Pedersen; T P Gibson
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

4.  Assessment of liver ability to biotransformation of antipyrine in uraemic patients on regular peritoneal dialysis treatment.

Authors:  A Grzegorzewska; Z Lowicki; E Chmara; A Mrozikiewicz; K Baczyk
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

5.  Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.

Authors:  J Kneer; Y K Tam; R A Blouin; F J Frey; E Keller; C Stathakis; B Luginbuehl; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

6.  Cefsulodin sodium therapy in cystic fibrosis patients.

Authors:  I Cabezudo; R L Thompson; R F Selden; S H Guenthner; R P Wenzel
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

7.  Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.

Authors:  I H Patel; J G Sugihara; R E Weinfeld; E G Wong; A W Siemsen; S J Berman
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

8.  Pharmacokinetics of cefotiam and cefsulodin after simultaneous administration to patients with impaired renal function.

Authors:  J B Lecaillon; M C Rouan; U Binswanger; J Guibert; J P Schoeller
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

Review 9.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

10.  Single-dose pharmacokinetics of cefsulodin in patients with cystic fibrosis.

Authors:  M D Reed; R C Stern; T S Yamashita; I Ackers; C M Myers; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.